Comparative Effectiveness of Online 8-session CBT Vs. 1-Session Empowered Relief for Chronic Pain - the PROGRESS Study
Launched by STANFORD UNIVERSITY · Nov 4, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The PROGRESS Study is a clinical trial designed to compare two different approaches for helping people manage chronic pain. One group of participants will receive 8 weeks of cognitive behavioral therapy (CBT), which involves a total of 16 hours of treatment aimed at changing the way they think about and respond to their pain. The other group will take part in a shorter, 1-session program called Empowered Relief, which focuses on teaching pain relief skills in just 2 hours. The study aims to see which method is more effective in helping individuals cope with their pain.
To participate in this study, you must be at least 18 years old and have chronic pain, meaning you experience pain on most days for three months or longer. Your average pain score should be at least a 3 out of 10 in the past month. It's important to note that those with certain conditions, like cognitive impairment or active suicidal thoughts, may not be eligible. If you decide to join, you can expect to either attend weekly sessions for the CBT program or participate in a single session for the Empowered Relief program. This research will help understand which treatment approach may be more beneficial for managing chronic pain.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. At least 18 years of age or older of either sex (and all genders).
- • 2. Chronic pain (pain that occurs on at least half of the days of 3 months or more).
- • 3. Past-month average pain intensity score of at least 3/10.
- • 4. Ability to adhere to and complete study protocols.
- Exclusion Criteria:
- • 1. Inability to provide informed consent.
- • 2. Cognitive impairment, non-English speaking, or psychological factors that would preclude comprehension of material and/or full participation in the study including group treatment.
- • 3. Active suicidality at screening.
- • 4. Study staff may exclude individuals with a known history of disruptive behavior to minimize contamination of the learning environment for an entire treatment cohort.
- • 5. Receipt of either study treatment in the past 3 months.
About Stanford University
Stanford University is a prestigious academic institution renowned for its cutting-edge research and innovation in healthcare and medicine. As a clinical trial sponsor, Stanford leverages its extensive resources, including a collaborative network of world-class researchers and state-of-the-art facilities, to advance medical knowledge and improve patient care. The university is committed to conducting rigorous, ethical research that adheres to the highest standards of scientific integrity, fostering an environment where groundbreaking discoveries can translate into effective clinical applications. Through its clinical trials, Stanford aims to address critical health challenges and contribute to the development of novel therapies and treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Phoenix, Arizona, United States
Allentown, Pennsylvania, United States
Salt Lake City, Utah, United States
Louisville, Kentucky, United States
Long Beach, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials